年龄相关性黄斑变性眼用新制剂的研究进展

Advances in ophthalmic drug delivery systems for the age-related macular degeneration

年龄相关性黄斑变性(AMD)是中老年人群主要的致盲性眼病之一。目前,以雷珠单抗为代表的抗血管内皮生长因子(VEGF)药物已成为临床公认的AMD一线治疗药物。但部分患者即使反复接受抗VEGF药物治疗后,视力仍无法得到提高或保持稳定,且承担着玻璃体腔注射术后严重并发症的风险。为进一步提高AMD的治疗效果,研发新的单用、联用药物以及多靶点治疗药物,已成为新的研究热点。近年来,以血小板衍生生长因子和补体为靶点的治疗药物已进入临床试验阶段,并取得令人欣喜的效果。本文综述了近年来国内外治疗AMD的眼用新制剂、联用策略和发展趋势,为今后AMD的治疗提供参考。

Age-related macular degeneration (AMD) is one of the largest blinding diseases for elder populations all over the world. Currently, Ranibizumab, an antibody against vascular endothelial growth factor (VEGF), has become a standard drug therapy for AMD;However, the declined therapeutic effects, retinal fibrosis, geographic atrophy and scarring are induced after long-term treatment. Therefore, the new drug development focusing on mono-therapy and/or combination with anti-VEGF antibody drugs, together with multi-target drugs are the most promising research in the future. Recently, the platelet derived growth factor and complement-targeting drugs have shown encouraging results in early-phase clinical trials. This paper reviews the recent advances in ophthalmic drug delivery system for AMD, and provides a reference for further treatment.